Latest Conference Articles

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.

Adults often do not suffer from the symptoms of hyperactivity in ADHD.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

Data show effectiveness of DSRM in treating major depressive disorder with less frequent discontinuations.

More research is needed to fully understand the associations with different types of strabismus

Late life depression is a known risk factor for dementia, impacting 8-16% in the US.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

New data show mental health workers experienced lower levels of traumatic stress and peritraumatic distress during COVID-19 pandemic, compared to healthcare workers and general population.

Despite higher risk of adverse effects in patients with opioid use disorder, benzodiazepine does not undo protection benefits of buprenorphine.

In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.

Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.

A new study from APA 2021 finds algorithm use can reduce clinical misdiagnosis of bipolar disorder as other mood disorders, including major depressive disorder.

The rates of both diseases have been increasingly linked in recent years.

Dr. Joshua Morganstein discusses the psychological impacts disasters can have on individuals and how the COVID-19 pandemic might be different than other disasters.

The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.

An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.

A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.

A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.